Conditions: Hepatic Impairment Healthy Participants
Keywords: PF-06651600 Pharmacokinetics Hepatic impairment
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 18
Healthy volunteers: yes

Brief summary:
The purpose of this study is to characterize the effect of hepatic impairment on the pharmacokinetic(s) (PK) of PF-06651600 following administration of multiple once daily doses of PF-06651600. The safety and tolerability of PF-06651600 will also be evaluated in this study.

Detailed description:

Arms:
arm 1: This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10. arm 2: This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10. arm 3: This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.

The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.

Interventions: intervention 1: PF-06651600 30 mg
Intervention descriptions: intervention 1: PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.

Protocol document:
Prot_000.pdf: 







































































































































































SAP_001.pdf: